Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 | Contract Pharma

What are you searching for?

Sign in

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MAP Pharmaceuticals’ initial Phase III trial of Unit Dose Budesonide (UDB) for the potential treatment of pediatric asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline in nighttime and daytime symptom scores, in either of the doses evaluated when compared with placebo.
 
AstraZeneca and MAP have a collaboration agreement to develop and commercialize UDB. The two companies will further analyze the data to determine appropriate next steps for the program.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters